MA47452A - Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancer - Google Patents
Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancerInfo
- Publication number
- MA47452A MA47452A MA047452A MA47452A MA47452A MA 47452 A MA47452 A MA 47452A MA 047452 A MA047452 A MA 047452A MA 47452 A MA47452 A MA 47452A MA 47452 A MA47452 A MA 47452A
- Authority
- MA
- Morocco
- Prior art keywords
- heterocyclylsulfonyl
- pyridines
- substitution
- cancer treatment
- cancer
- Prior art date
Links
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000006467 substitution reaction Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455644P | 2017-02-07 | 2017-02-07 | |
| US201762594784P | 2017-12-05 | 2017-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47452A true MA47452A (fr) | 2019-12-18 |
Family
ID=61231287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047452A MA47452A (fr) | 2017-02-07 | 2018-02-07 | Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11168069B2 (fr) |
| EP (1) | EP3580209A1 (fr) |
| JP (1) | JP2020506244A (fr) |
| KR (1) | KR20190115012A (fr) |
| CN (1) | CN110382480A (fr) |
| AU (1) | AU2018218521C1 (fr) |
| BR (1) | BR112019016233A2 (fr) |
| CA (1) | CA3051538A1 (fr) |
| MA (1) | MA47452A (fr) |
| MX (1) | MX389800B (fr) |
| WO (1) | WO2018146471A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| AU2018218518B2 (en) | 2017-02-07 | 2022-03-17 | Oblique Therapeutics Ab | Sulfinylpyridines and their use in the treatment of cancer |
| BR112019016223A2 (pt) | 2017-02-07 | 2020-04-07 | Oblique Therapeutics Ab | piridinas substituídas por heteroarilsulfonila e uso das mesmas no tratamento de câncer |
| RU2019128063A (ru) | 2017-02-07 | 2021-03-09 | Облик Терапьютикс Аб | Углеводородсульфонилзамещенные пиридины и их применение при лечении рака |
| SG11202007535VA (en) * | 2018-02-12 | 2020-09-29 | Cinda Pharma Ab | Thioredoxin reductase inhibitors for use in the treatment of cancer |
| CN112996795B (zh) | 2018-09-18 | 2024-11-12 | 尼坎治疗公司 | 作为src同源-2磷酸酶抑制剂的稠合的三环衍生物 |
| CN112955214B (zh) | 2018-10-29 | 2024-05-07 | 勃林格殷格翰国际有限公司 | 吡啶基磺酰胺衍生物、药物组合物及其用途 |
| CN112955215B (zh) | 2018-10-29 | 2024-05-17 | 勃林格殷格翰国际有限公司 | 吡啶基磺酰胺衍生物、药物组合物及其用途 |
| KR102919383B1 (ko) | 2022-11-09 | 2026-01-28 | 한국생산기술연구원 | 정전압 압전기화학 분석 방법 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3064846D1 (en) * | 1979-12-19 | 1983-10-20 | Duphar Int Res | New nitrothiophenes, method of preparing the new compounds, as well as fungicidal and/or bactericidal compositions on the basis of the new compounds |
| US4456469A (en) | 1980-03-07 | 1984-06-26 | E. I. Du Pont De Nemours And Company | Pyridyl sulfone herbicides |
| AU543161B2 (en) | 1980-03-07 | 1985-04-04 | E.I. Du Pont De Nemours And Company | Pyrimidine or s.triazine derivatives |
| US4791127A (en) | 1985-10-07 | 1988-12-13 | Nippon Kayaku Kabushiki Kaisha | Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides |
| DE3812177A1 (de) | 1988-04-13 | 1989-10-26 | Bayer Ag | 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung |
| AU2395095A (en) | 1994-04-29 | 1995-11-29 | G.D. Searle & Co. | Method of using (h+/k+) atpase inhibitors as antiviral agents |
| US6069144A (en) | 1995-08-24 | 2000-05-30 | Basf Aktiengesellschaft | N-heterocyclic compounds, intermediate products used to prepare them, agents containing them and their use in antifungal applications |
| DE19531148A1 (de) | 1995-08-24 | 1997-02-27 | Basf Ag | Fungizide Pyridin-2-yl-Derivate |
| WO1998054139A1 (fr) | 1997-05-30 | 1998-12-03 | Basf Aktiengesellschaft | Procede de fabrication de thiopyridines substituees |
| US6284923B1 (en) | 1997-08-22 | 2001-09-04 | Tularik Inc | Substituted benzene compounds as antiproliferative and cholesterol lowering action |
| JP2001519345A (ja) | 1997-10-02 | 2001-10-23 | メルク エンド カムパニー インコーポレーテッド | プレニルタンパク質トランスフェラーゼの阻害剤 |
| US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6191170B1 (en) | 1998-01-13 | 2001-02-20 | Tularik Inc. | Benzenesulfonamides and benzamides as therapeutic agents |
| EP0930302B1 (fr) | 1998-01-16 | 2003-04-02 | F.Hoffmann-La Roche Ag | Dérivés de benzosulfone |
| AU2001250783A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| WO2003068744A1 (fr) | 2002-02-18 | 2003-08-21 | Ishihara Sangyo Kaisha, Ltd. | Derives de la pyridine ou leurs sels, et inhibiteurs de production de citokine renfermant ces derives |
| US20030236287A1 (en) | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
| US7037902B2 (en) | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
| EP1651595A2 (fr) | 2003-05-30 | 2006-05-03 | Rigel Pharmaceuticals, Inc. | Inhibiteurs de ligase d'ubiquitine |
| HRP20090093T3 (en) | 2004-06-04 | 2009-03-31 | Arena Pharmaceuticals Inc. | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| US20060019967A1 (en) | 2004-07-21 | 2006-01-26 | Su-Ying Wu | SARS CoV main protease inhibitors |
| GB0426313D0 (en) | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
| WO2006083692A2 (fr) | 2005-01-28 | 2006-08-10 | Mount Sinai Schoool Of Medicine | Procédés d'identification de modulateurs de bromodomaines |
| GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| US20100048713A1 (en) | 2006-01-06 | 2010-02-25 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| AU2007246172A1 (en) | 2006-04-28 | 2007-11-08 | Avexa Limited | Integrase inhibitors 3 |
| US20090005422A1 (en) * | 2006-05-22 | 2009-01-01 | Thioredoxin Systems Ab | Bacterial thioredoxin reductase inhibitors and methods for use thereof |
| MX2010000617A (es) | 2007-07-17 | 2010-05-17 | Plexxikon Inc | Compuestos y metodos para modulacion de cinasa, e indicaciones de estos. |
| CN101723932B (zh) | 2008-10-31 | 2013-11-20 | 北京以岭生物工程技术有限公司 | 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途 |
| AU2010253820A1 (en) | 2009-05-28 | 2011-12-22 | President And Fellows Of Harvard College | N,N-diarylurea compounds and N,N'-diarylthiourea compounds as inhibitors of translation initiation |
| CA2771190C (fr) | 2009-08-17 | 2020-01-21 | Memorial Sloan-Kettering Cancer Center | Composes de liaison a une proteine de choc thermique, compositions et procedes pour les fabriquer et les utiliser |
| EP2535059A4 (fr) | 2010-02-10 | 2014-03-12 | Public Univ Corp Yokohama City | Utilisation d'un composé se liant à msin3b qui se lie, de façon spécifique, au facteur silenceur de la spécification neuronale nrsf |
| EP2536411A4 (fr) * | 2010-02-18 | 2013-08-07 | Univ Princeton | Inhibiteurs du métabolisme d'acide gras à longue et très longue chaîne comme antiviraux à large spectre |
| CN102206172B (zh) | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | 一组取代双芳基化合物及其制备方法和抗病毒应用 |
| WO2012025638A1 (fr) | 2010-08-27 | 2012-03-01 | Universität des Saarlandes | Inhibiteurs sélectifs de la 17-bêta-hydroxystéroïde déshydrogénase de type 1 |
| WO2013119931A1 (fr) | 2012-02-10 | 2013-08-15 | The Board Of Regents Of The University Of Texas System | Modulateurs de protéines d'échange directement activées par l'ampc (epac) |
| US8946418B1 (en) | 2013-07-10 | 2015-02-03 | Boehringer Ingelheim International Gmbh | Chiral nitrogen-phosphorus ligands and their use for asymmetric hydrogenation of alkenes |
| CN104672214B (zh) | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
| CN105503827B (zh) | 2014-10-11 | 2019-09-24 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备方法和用途 |
| CN105085483B (zh) | 2015-06-04 | 2019-01-01 | 湖北生物医药产业技术研究院有限公司 | 激酶抑制剂及其应用 |
| CN104987324B (zh) | 2015-06-04 | 2018-05-04 | 湖北生物医药产业技术研究院有限公司 | 作为alk抑制剂的嘧啶衍生物 |
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| RU2019128063A (ru) | 2017-02-07 | 2021-03-09 | Облик Терапьютикс Аб | Углеводородсульфонилзамещенные пиридины и их применение при лечении рака |
| BR112019016223A2 (pt) | 2017-02-07 | 2020-04-07 | Oblique Therapeutics Ab | piridinas substituídas por heteroarilsulfonila e uso das mesmas no tratamento de câncer |
| AU2018218518B2 (en) | 2017-02-07 | 2022-03-17 | Oblique Therapeutics Ab | Sulfinylpyridines and their use in the treatment of cancer |
-
2018
- 2018-02-07 MX MX2019009354A patent/MX389800B/es unknown
- 2018-02-07 AU AU2018218521A patent/AU2018218521C1/en not_active Ceased
- 2018-02-07 CN CN201880010203.5A patent/CN110382480A/zh active Pending
- 2018-02-07 WO PCT/GB2018/050345 patent/WO2018146471A1/fr not_active Ceased
- 2018-02-07 KR KR1020197024690A patent/KR20190115012A/ko not_active Ceased
- 2018-02-07 BR BR112019016233A patent/BR112019016233A2/pt not_active IP Right Cessation
- 2018-02-07 EP EP18705719.5A patent/EP3580209A1/fr not_active Withdrawn
- 2018-02-07 JP JP2019563698A patent/JP2020506244A/ja active Pending
- 2018-02-07 MA MA047452A patent/MA47452A/fr unknown
- 2018-02-07 CA CA3051538A patent/CA3051538A1/fr active Pending
- 2018-02-07 US US16/483,961 patent/US11168069B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20200024255A1 (en) | 2020-01-23 |
| MX389800B (es) | 2025-03-20 |
| WO2018146471A1 (fr) | 2018-08-16 |
| JP2020506244A (ja) | 2020-02-27 |
| CA3051538A1 (fr) | 2018-08-16 |
| BR112019016233A2 (pt) | 2020-04-07 |
| KR20190115012A (ko) | 2019-10-10 |
| EP3580209A1 (fr) | 2019-12-18 |
| MX2019009354A (es) | 2019-09-19 |
| CN110382480A (zh) | 2019-10-25 |
| AU2018218521A1 (en) | 2019-08-15 |
| AU2018218521C1 (en) | 2022-06-09 |
| AU2018218521B2 (en) | 2021-11-25 |
| RU2019127886A3 (fr) | 2021-05-17 |
| RU2019127886A (ru) | 2021-03-10 |
| US11168069B2 (en) | 2021-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47452A (fr) | Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancer | |
| MA43163A (fr) | Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer | |
| MA45122A (fr) | Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer | |
| MA47458A (fr) | Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer | |
| MA47451A (fr) | Pyridines à substitution hétéroarylsulfonyle et leur utilisation dans le traitement du cancer | |
| MA52886A (fr) | Composés de purinone et leur utilisation dans le traitement du cancer | |
| SI3661954T1 (sl) | Muteini interlevkina-21 in postopki zdravljenja | |
| MA42915A (fr) | Pyridines et leur utilisation dans le traitement du cancer | |
| PL3303632T3 (pl) | Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze | |
| IL256687B (en) | Isolated tau-binding antibody and use thereof in therapy and diagnosis | |
| MA39960A (fr) | Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer | |
| HUE054548T2 (hu) | Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében | |
| DK3134125T3 (da) | Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer | |
| IL255119B (en) | Therapeutic pooled blood apoptotic cell preparations and uses thereof | |
| EP3937980A4 (fr) | Miarn modifiés et leur utilisation dans le traitement du cancer | |
| EP3448263A4 (fr) | Traitement électrothérapeutique | |
| SI3319612T1 (sl) | Oksisteroli in postopki za uporabo le-teh | |
| MA41316A (fr) | Gènes de détermination du sexe et leur utilisation en reproduction | |
| MA47450A (fr) | Sulfinylpyridines et leur utilisation dans le traitement du cancer | |
| MA47408A (fr) | Traitement du cancer | |
| EP3713289A4 (fr) | Procédé de traitement de requêtes, et entité correspondante | |
| EP3258964A4 (fr) | Détection et traitement de tumeurs malignes dans le snc | |
| EP3733175A4 (fr) | Traitement du cancer | |
| DK3270990T3 (da) | Hængslet skjoldanordning og beslægtede fremgangsmåder | |
| MA45046A (fr) | Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules |